United States Assisted Reproductive Technology Market Size, Trends & Forecast 2025–2033 | Renub Research

United States Assisted Reproductive Technology Market Overview

The United States Assisted Reproductive Technology (ART) Market is undergoing steady and transformative growth as infertility challenges rise alongside rapid advancements in reproductive medicine. According to Renub Research, the U.S. ART market is expected to reach US$ 9.31 billion by 2033, up from US$ 6.01 billion in 2024, registering a compound annual growth rate (CAGR) of 4.98% from 2025 to 2033.

Download Free Sample Report

This growth trajectory reflects a convergence of social, medical, and technological factors. Rising infertility rates, delayed parenthood, increasing awareness of fertility solutions, broader acceptance of assisted conception, and innovations such as genetic testing and embryo freezing are all fueling market expansion. Additionally, improving insurance coverage in select states and employer-sponsored fertility benefits are making ART services more accessible to a broader segment of the population.

Assisted reproductive technology has moved beyond being a niche medical solution to becoming a mainstream healthcare service in the United States, supported by evolving family structures, inclusive fertility policies, and rising investment in reproductive health infrastructure.

What Is Assisted Reproductive Technology (ART)?

Assisted Reproductive Technology (ART) refers to a range of medical procedures used to treat infertility by handling eggs, sperm, or embryos outside the human body to achieve pregnancy. These procedures are typically performed in specialized fertility clinics and hospitals under the supervision of reproductive endocrinologists.

Common ART procedures include:

In Vitro Fertilization (IVF)

Intracytoplasmic Sperm Injection (ICSI)

Artificial Insemination (AI-IUI)

Frozen Embryo Transfer (FET)

Embryo, egg, and sperm cryopreservation

Use of donor eggs or sperm

ART is frequently used when conventional fertility treatments fail or in cases of advanced maternal age, unexplained infertility, genetic disorders, or same-sex family planning. Over the past few decades, ART has helped millions of individuals and couples in the U.S. realize their goal of parenthood, transforming reproductive healthcare outcomes nationwide.

United States Assisted Reproductive Technology Market Outlook

The U.S. ART market is expanding steadily due to greater public awareness and social acceptance of fertility treatments. Government agencies, nonprofit organizations, and professional medical bodies are actively educating the public about infertility causes, treatment options, and the importance of early intervention.

Public discussions by celebrities and public figures openly sharing their experiences with IVF, egg freezing, surrogacy, and infertility struggles have played a critical role in reducing stigma. As a result, more individuals are proactively seeking fertility evaluations and treatment at earlier stages.

Strategic collaborations are also shaping the industry. In October 2024, the Society for Reproductive Biologists and Technologists (SRBT) partnered with the American Society for Reproductive Medicine (ASRM) to launch the ASRM Clinical Embryology Learning Laboratory (CELL). This initiative aims to strengthen workforce training and enhance clinical standards across fertility laboratories in the U.S., reinforcing long-term market sustainability.

Key Growth Drivers of the U.S. Assisted Reproductive Technology Market

Growing Utilization of Preimplantation Genetic Testing (PGT)

Preimplantation Genetic Testing (PGT) has become a critical component of modern ART procedures in the U.S. This technology allows clinicians to screen embryos for chromosomal abnormalities and inherited genetic disorders before implantation, significantly improving IVF success rates.

Advancements in Next-Generation Sequencing (NGS) have enhanced the accuracy of PGT-A (aneuploidy testing), making it especially popular among older patients and individuals with repeated IVF failures. By identifying the healthiest embryos, PGT supports precision medicine approaches, reduces miscarriage risk, and improves live birth outcomes.

As patients increasingly prioritize informed decision-making and treatment efficiency, demand for genetic testing within ART protocols continues to rise across fertility clinics nationwide.

Advancements in Artificial Intelligence and IVF Automation

Artificial Intelligence (AI) and automation technologies are rapidly transforming the U.S. ART landscape by improving accuracy, efficiency, and consistency in fertility treatments. AI-powered time-lapse embryo imaging systems, such as EmbryoScope, allow continuous monitoring of embryo development, providing valuable insights into embryo viability.

Innovative companies like TMRW Life Sciences and Alife Health are developing automated laboratory solutions that minimize human error, enhance cryostorage safety, and streamline clinical workflows. AI-based data platforms are also being used to personalize treatment protocols by analyzing patient history, hormonal responses, and embryo development patterns.

In July 2024, Canada-based Hamilton Thorne Ltd. launched EmbryoView Pro, an advanced AI-driven embryo monitoring system designed to deliver real-time embryo assessment and improved ART outcomes. This launch highlights the growing integration of digital intelligence in reproductive medicine and its impact on clinical success rates.

Rising Demand for Fertility Preservation and Egg Freezing

Fertility preservation, particularly egg freezing, has gained widespread popularity in the United States. Women are increasingly choosing to delay childbirth due to career goals, education, financial planning, or personal circumstances. Improvements in vitrification techniques have significantly enhanced egg survival and pregnancy success rates after thawing.

Many major U.S. corporations—including Google, Apple, and Meta—now include fertility preservation benefits in employee healthcare packages, further driving adoption. Women in their late 20s and early 30s are increasingly opting for egg freezing as a proactive measure against age-related fertility decline.

Fertility clinics are actively promoting preservation services as a form of “reproductive insurance,” empowering individuals to take control of their reproductive timelines. This shift reflects evolving social norms and increased acceptance of technology-assisted family planning.

Challenges Facing the U.S. Assisted Reproductive Technology Market

High Cost of Treatment

Despite growing demand, the high cost of ART treatments remains a major barrier. A single IVF cycle in the U.S. can cost between US$ 12,000 and US$ 20,000, excluding medications, genetic testing, and embryo storage fees. Many patients require multiple cycles to achieve success, significantly increasing the financial burden.

Insurance coverage remains inconsistent across states, and many plans offer limited or no fertility benefits. This creates disparities in access, particularly for middle-income and lower-income families, reinforcing socioeconomic inequalities in reproductive healthcare.

Regulatory and Policy Challenges

The U.S. ART market also faces regulatory complexity due to the lack of uniform federal oversight. Fertility clinics primarily operate under self-regulation, leading to variations in clinical standards, reporting practices, and transparency.

State-level differences in legislation regarding insurance mandates, embryo storage, and ethical considerations further complicate market operations. The absence of comprehensive enforcement mechanisms creates uncertainty for both patients and providers, potentially limiting long-term market growth and public trust.

United States Assisted Reproductive Technology Market Segmentation

By Technology

In Vitro Fertilization (IVF)

Artificial Insemination (AI-IUI)

Frozen Embryo Transfer (FET)

Others

IVF remains the dominant segment due to higher success rates and expanding technological advancements, while FET is gaining traction with the growing use of embryo freezing.

By End Use

Hospitals

Fertility Clinics

Other End Users / Providers

Specialized fertility clinics lead the market due to their advanced infrastructure, experienced specialists, and comprehensive ART service offerings.

Key Players in the U.S. Assisted Reproductive Technology Market

Leading companies are focusing on innovation, partnerships, and geographic expansion to strengthen their market position. Key players include:

Cosmos Biomedical Ltd.

Microm U.K. Ltd.

CooperSurgical, Inc.

FUJIFILM Irvine Scientific, Inc.

Cryolab Ltd.

Vitrolife AB

Merck KGaA

Ferring B.V.

Each company is analyzed based on company overview, key personnel, recent developments and strategies, and sales performance, highlighting their contribution to the evolving U.S. ART ecosystem.

Final Thoughts

The United States Assisted Reproductive Technology Market is poised for sustained growth through 2033, driven by technological innovation, increasing awareness, and changing societal attitudes toward fertility care. While challenges such as high costs and regulatory inconsistencies persist, advancements in AI, genetic testing, and fertility preservation are redefining treatment success and accessibility.

As healthcare systems, employers, and policymakers continue to recognize fertility as a critical component of reproductive health, ART is expected to play an increasingly central role in shaping the future of family building in the United States.

With a projected market size of US$ 9.31 billion by 2033, the U.S. ART industry stands at the intersection of medical innovation and social transformation—offering hope, choice, and possibility to millions.